$GILD Recent Headlines 3 top trades for 2014 6:00 a.m.

New Post Public Reply Private Reply Replies (0) Message Board

Jan 2, 2014 at 11:13 AM

$GILD Recent Headlines

3 top trades for 2014 6:00 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - blogs.marketwatch.com
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Saumya Vaishampayan
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:18 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - blogs.marketwatch.com
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 12:23 p.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 6:13 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 5:06 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 4:58 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 9:52 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 3:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 8:20 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 4:20 p.m. Oct. 10, 2013 - Saumya Vaishampayan
Best Buy, Gilead Sciences lead S&P 500 gainers 4:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 11:27 a.m. Oct. 10, 2013 - blogs.marketwatch.com
Gilead ends leukemia study after positive results 5:09 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 5:05 p.m. Oct. 9, 2013 - Wallace Witkowski

Maxim hikes target on Gilead as Sovaldi continues to impress 28 min ago - Seeking Alpha
UBS Top High Conviction Stock Picks for 2014 7:46 a.m. Today - 247WallSt.com
The Top Five Drug Launches Of 2013 12:42 p.m. Dec. 31, 2013 - Investors Business Daily
Deutsche still bullish on Gilead after Sovaldi launch 10:36 a.m. Dec. 31, 2013 - Seeking Alpha
Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 31, 2013 - Zacks.com
Growth Portfolio Super Bowl 2:03 a.m. Dec. 31, 2013 - Seeking Alpha
All 10 Stock Sectors Post Gains in Big Year 10:18 p.m. Dec. 30, 2013 - WSJ.com
Update on RedHill Biopharma's Pipeline - Analyst Blog 6:30 p.m. Dec. 30, 2013 - Zacks.com
Should You Sell Gilead Sciences After A Successful 2013? 1:00 p.m. Dec. 30, 2013 - Seeking Alpha
Weekly CFO Sells Highlight: Facebook Inc., Google Inc., Verisk Analytics Inc., Gilead Sciences Inc. 10:27 a.m. Dec. 30, 2013 - GuruFocus.com
The Best Mutual Funds of 2013 9:13 a.m. Dec. 30, 2013 - InvestorPlace.com
Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More 8:05 a.m. Dec. 30, 2013 - 247WallSt.com
On the Road to Riches in Biotech 4:10 a.m. Dec. 28, 2013 - Barrons.com
Merck Plans Radical Overhaul of Drug R&D Unit 5:20 p.m. Dec. 27, 2013 - WSJ.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 5:01 p.m. Dec. 27, 2013 - TheStreet.com
Genomic Health Remains Neutral - Analyst Blog 2:55 p.m. Dec. 27, 2013 - Zacks.com
Dynavax Submits Response to EMA - Analyst Blog 12:10 p.m. Dec. 24, 2013 - Zacks.com
Gilead Sciences And The Numbers Game 9:51 a.m. Dec. 23, 2013 - Seeking Alpha
Gilead Sciences Inc's Buy Recommendation Supported 9:00 a.m. Dec. 23, 2013 - TheStreet.com
2 Big Biotechs Moving Up On News 12:10 p.m. Dec. 20, 2013 - Seeking Alpha

Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire
Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 8:30 a.m. Dec. 16, 2013 - BusinessWire
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(R) for Patients Switching from a Stable Regimen 4:30 p.m. Dec. 13, 2013 - BusinessWire
HealthStat Rx: Curing Hepatitis C (HCV) With Confidence 10:07 a.m. Dec. 12, 2013 - BusinessWire
Here to Track Insider Trading of Gilead Sciences, Microsoft, Halliburton 8:55 a.m. Dec. 11, 2013 - PR Newswire
Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz Pharmaceuticals, CSI, and Smith & Nephew 8:00 a.m. Dec. 11, 2013 - PR Newswire
Final Hour Buzz: Gilead Sciences, MannKind Corporation, Facebook Inc, Tiger Oil and Energy 2:46 p.m. Dec. 10, 2013 - ACCESSWIRE
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology 11:00 a.m. Dec. 9, 2013 - ACCESSWIRE
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma 8:00 a.m. Dec. 9, 2013 - PR Newswire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 6:00 p.m. Dec. 8, 2013 - BusinessWire
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 6:30 p.m. Dec. 7, 2013 - BusinessWire
U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 4:19 p.m. Dec. 6, 2013 - BusinessWire
Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 5:00 p.m. Dec. 2, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...